Synlogic (Synlogic) 3-Year EBITDA Growth Rate : 28.90% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Synlogic 3-Year EBITDA Growth Rate?

Synlogic's EBITDA per Share for the three months ended in Dec. 2023 was $-1.54.

During the past 3 years, the average EBITDA Per Share Growth Rate was 28.90% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 21.10% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 28.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Synlogic was 61.90% per year. The lowest was -104.90% per year. And the median was 22.50% per year.

Competitive Comparison of Synlogic's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Synlogic's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Synlogic's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synlogic's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Synlogic's 3-Year EBITDA Growth Rate falls into.

Synlogic 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Synlogic (NAS:SYBX) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Synlogic 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Synlogic's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Synlogic (Synlogic) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synlogic Inc (NAS:SYBX) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

0A8U:UK

Address

301 Binney Street, Suite 402, Cambridge, MA, USA, 02142

Website

https://www.synlogictx.com

Synlogic Inc is a biopharmaceutical company focused on the discovery and development of Synthetic Biotic medicines that are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways, or deliver combinations of therapeutic factors. Synthetic Biotic medicines are generated from the company's proprietary drug discovery and development platform, using Synthetic Biology and leveraging a reproducible, modular approach to develop beneficial microbes that perform or deliver critical therapeutic functions. Its key product candidate is SYNB1618, an oral therapy intended for the treatment of PKU, a rare metabolic disease in which an amino acid known as phenylalanine accumulates in the body as a result of genetic defects.

Executives

Michael Vangsted Jensen	officer: Chief Financial Officer	301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Aoife Brennan	officer: Chief Medical Officer	200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Antoine Awad	officer: Chief Operating Officer	C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Lisa Kelly-croswell	director	C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Michael Thomas Heffernan	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Michael F. Burgess	director	C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMRIDGE MA 02142
Richard P Shea	director	C/O MOMENTA PHARMACEUTICALS, INC., 43 MOULTON STREET, CAMBRIDGE MA 02138
Gregg Beloff	officer: See Remarks	C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Richard J. Riese	officer: Chief Medical Officer	C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Ginkgo Bioworks, Inc.	10 percent owner	27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Scott Eric Plevy	officer: Chief Scientific Officer	301 BINNEY STREET, #402, C/O SYNLOGIC, INC., CAMBRIDGE MA 02142
Paul Francis Miller	officer: Chief Scientific Officer	200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Patricia N. Hurter	director	C/O SYNLOGIC, INC., 301 BINNEY ST., SUITE 402, CAMBRIDGE MA 02142
Andrew Gengos	officer: See Remarks	21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Todd Shegog	officer: See Remarks	200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139